Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Blood (2024) 144 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2024-201086

Published: 2024

Journal Articles

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Martin F. Kaiser, Rachel Phillip, Andrew Hall, Amy Holroyd, Laura Bevington, Ruth M de Tute, Laura Clayton, Sadie Roberts, Graham Jackson, Gordon Cook, Richard S Houlston, Mark Drayson, Roger Owen, Guy Pratt, Sarah R Brown, Matthew W. Jenner

Blood (2023) 142 (Supplement 1): 881.

https://doi.org/10.1182/blood-2023-177896

Published: 2023

Journal Articles

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Isabelle Smith, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Mark T Drayson, Roger G Owen, Sarah R Brown, Matthew W Jenner

Blood (2022) 140 (Supplement 1): 1833–1835.

https://doi.org/10.1182/blood-2022-159540

Published: 2022

Journal Articles

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Blood (2019) 134 (Supplement_1): 1740.

https://doi.org/10.1182/blood-2019-122037

Published: 2019

Journal Articles

Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia

Blood (2019) 134 (Supplement_1): 650.

https://doi.org/10.1182/blood-2019-125791

Published: 2019

Journal Articles

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk

Amit Sud, Subhayan Chattopadhyay, Hauke Thomsen, Kristina Sundquist, Jan Sundquist, Richard S. Houlston, Kari Hemminki

Blood (2019) 134 (12): 960–969.

https://doi.org/10.1182/blood.2019001362

Published: 2019

Includes: Supplemental data

Journal Articles

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Blood (2018) 132 (23): 2465–2469.

https://doi.org/10.1182/blood-2018-06-857250

Published: 2018

Includes: Supplemental data

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma

Blood (2018) 132 (19): 2040–2052.

https://doi.org/10.1182/blood-2018-06-855296

Published: 2018

Includes: Supplemental data

Journal Articles

Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms

Amit Sud, Subhayan Chattopadhyay, Hauke Thomsen, Kristina Sundquist, Jan Sundquist, Richard S. Houlston, Kari Hemminki

Blood (2018) 132 (9): 973–976.

https://doi.org/10.1182/blood-2018-06-858597

Published: 2018

Includes: Supplemental data

Journal Articles

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

Laura Hinze, Stefanie V. Junk, PhD, Norman Klein, Anja Moricke, MD, Gunnar Cario, MD, Christian P. Kratz, MD, Richard S Houlston, MD PhD, Claus R Bartam, MD, Rolf Koehler, PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 3981.

https://doi.org/10.1182/blood.V130.Suppl_1.3981.3981

Published: 2017

Journal Articles

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

Blood (2017) 130 (Supplement 1): 4331.

https://doi.org/10.1182/blood.V130.Suppl_1.4331.4331

Published: 2017

Journal Articles

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Karen Menezes, PhD BSc, MSc, Grace Aram, MSc, Fabio Mirabella, PhD, David C Johnson, PhD, Amy L Sherborne, PhD, Richard S Houlston, MD PhD, Matthew D Cheeseman, PhD, Elisa Pasqua, PhD, Paul Clarke, PhD, Paul Workman, PhD, Keith Jones, PhD, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 3072.

https://doi.org/10.1182/blood.V130.Suppl_1.3072.3072

Published: 2017

Journal Articles

Neutral tumor evolution in myeloma is associated with poor prognosis

David C. Johnson, Oleg Lenive, Jonathan Mitchell, Graham Jackson, Roger Owen, Mark Drayson, Gordon Cook, John R. Jones, Charlotte Pawlyn, Faith E. Davies, Brian A. Walker, Christopher Wardell, Walter M. Gregory, David Cairns, Gareth J. Morgan, Richard S. Houlston, Martin F. Kaiser

Blood (2017) 130 (14): 1639–1643.

https://doi.org/10.1182/blood-2016-11-750612

Published: 2017

Includes: Supplemental data

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia

Helen E. Speedy, Ben Kinnersley, Daniel Chubb, Peter Broderick, Philip J. Law, Kevin Litchfield, Sandrine Jayne, Martin J. S. Dyer, Claire Dearden, George A. Follows, Daniel Catovsky, Richard S. Houlston

Blood (2016) 128 (19): 2319–2326.

https://doi.org/10.1182/blood-2016-01-695692

Published: 2016

Includes: Supplemental data

Journal Articles

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Martin F Kaiser, MD, Eileen Mary Boyle, MD PhD, Brian A Walker, PhD, Dil B Begum, Paula Proszek, David C Johnson, PhD, Charlotte Pawlyn, MB BChir, John R Jones, MD, Suvi Savola, PhD, Roger G Owen, Mark T Drayson, MD PhD, David A Cairns, Gordon Cook, MD PhD, Walter M Gregory, Richard S Houlston, MDPhDFRCP, Faith E Davies, MD, Graham H Jackson, MD, Gareth J Morgan, MD PhD

Blood (2015) 126 (23): 2981.

https://doi.org/10.1182/blood.V126.23.2981.2981

Published: 2015

Journal Articles

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Blood (2015) 126 (23): 371.

https://doi.org/10.1182/blood.V126.23.371.371

Published: 2015

Journal Articles

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Blood (2015) 126 (23): 2983.

https://doi.org/10.1182/blood.V126.23.2983.2983

Published: 2015

NARROW

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia

Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk

Subclonal TP53 copy number is associated with prognosis in multiple myeloma

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma

Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

Molecular Characterisation of TP53 Aberrations in 1,777 Myeloma Trial Patients

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Neutral tumor evolution in myeloma is associated with poor prognosis

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only